What is the current Measles, Mumps and Rubella Virus Vaccine Live market size?

The Measles, Mumps and Rubella Virus Vaccine Live market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Measles, Mumps and Rubella Virus Vaccine Live market?

Key drivers include rising vaccination rates and government initiatives to prevent outbreaks.

What are the major challenges faced by the market?

Challenges include vaccine hesitancy, supply chain disruptions, and stringent regulatory requirements.

Which regions are the leaders in the Measles, Mumps and Rubella Virus Vaccine Live market?

North America and Europe are the leading regions, driven by high vaccination rates and awareness.

Who are the top companies in the Measles, Mumps and Rubella Virus Vaccine Live market?

Top companies include GlaxoSmithKline, Merck, and Sanofi, which dominate the market with their vaccine products.

What are the future opportunities in the Measles, Mumps and Rubella Virus Vaccine Live market?

Future opportunities include emerging markets, increasing demand for combination vaccines, and advancements in vaccine technology.

How is technology impacting the Measles, Mumps and Rubella Virus Vaccine Live market?

Technology is improving vaccine development, manufacturing, and distribution, enabling more efficient and effective vaccine production.

What is the regulatory landscape like for the Measles, Mumps and Rubella Virus Vaccine Live market?

The regulatory landscape is stringent, with agencies such as the FDA and EMA overseeing vaccine approval, safety, and efficacy.

What is the future outlook for the Measles, Mumps and Rubella Virus Vaccine Live market?

The future outlook is positive, with increasing demand, advancements in technology, and growing awareness driving market growth.

Measles, Mumps and Rubella Virus Vaccine Live Market Growing at CAGR — 2026 Report

Measles, Mumps and Rubella Virus Vaccine Live by Application (Hospital, Community), by Types (Child, Adult), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 73

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 73

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Measles, Mumps and Rubella Virus Vaccine Live Market Size | CAGR 8.2 Forecast 2033

Measles, Mumps and Rubella Virus Vaccine Live Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 73

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 73

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Measles, Mumps and Rubella Virus Vaccine Live Market Overview

The Measles, Mumps and Rubella Virus Vaccine Live market refers to the global industry involved in the development, production, and distribution of live vaccines used to prevent measles, mumps, and rubella. As a crucial sector in the healthcare industry, the Measles, Mumps and Rubella Virus Vaccine Live market size was approximately $2.5 billion in 2025. The growth outlook for this market is promising, with a market forecast expecting significant expansion driven by increasing demand for vaccines, particularly in developing countries. The industry expansion is expected to be fueled by a compound annual growth rate (CAGR) of around 5%, driven by macro drivers such as government initiatives to improve vaccination rates and technological advancements in vaccine development. Key forces shaping the industry include technology shifts towards more effective and safer vaccines, regulations and standards set by global health organizations, and changing consumer behavior towards preventive healthcare.

Loading chart…

The largest region in the Measles, Mumps and Rubella Virus Vaccine Live market is North America, followed by Europe, while the fastest-growing region is expected to be the Asia-Pacific, driven by increasing government initiatives to improve vaccination rates and a growing awareness of preventive healthcare. Overall, the Measles, Mumps and Rubella Virus Vaccine Live market is poised for significant growth, driven by a combination of technological advancements, changing consumer behavior, and government initiatives to improve public health.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	24.05 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Shanghai Institute of Biological Products; Beijing Tiantan Biological Products
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Measles, Mumps and Rubella Virus Vaccine Live market is poised for significant growth, driven by increasing demand for effective vaccines and rising awareness about the importance of immunization. The Measles, Mumps and Rubella Virus Vaccine Live market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Increasing government initiatives and funding for vaccination programs, particularly in developing countries, are expected to drive the growth of the Measles, Mumps and Rubella Virus Vaccine Live market

Advances in vaccine technology and the development of new, more effective vaccine formulations are also contributing to the growth of the Measles, Mumps and Rubella Virus Vaccine Live market size

Restraints2 items

Stringent regulatory requirements and high development costs for new vaccines are major restraints on the growth of the Measles, Mumps and Rubella Virus Vaccine Live market

Public misconceptions and concerns about vaccine safety and efficacy also pose a significant challenge to the growth forecast of the Measles, Mumps and Rubella Virus Vaccine Live market

Opportunities2 items

Emerging markets in developing countries offer significant opportunities for growth, driven by increasing demand for vaccines and improving healthcare infrastructure

Partnerships and collaborations between vaccine manufacturers, governments, and non-governmental organizations can also drive growth and improve access to vaccines in underserved regions

Challenges2 items

Supply chain disruptions and vaccine shortages can have a significant impact on the Measles, Mumps and Rubella Virus Vaccine Live market size, particularly in areas with limited access to healthcare

Intense competition among vaccine manufacturers and pricing pressures can also pose a challenge to the growth forecast of the Measles, Mumps and Rubella Virus Vaccine Live market

Market Segmentation

Loading chart…

The Measles, Mumps and Rubella Virus Vaccine Live segmentation is categorized based on Application and Types. The Application segment refers to the different areas where the vaccine is used, such as pediatric and adult vaccination programs. This segment contributes significantly to the overall market size, as the demand for vaccines varies across different age groups and geographic regions.

The Types segment includes subtypes such as Monovalent, Bivalent, and Trivalent vaccines. Each subtype has its own unique characteristics and is used to target specific diseases. For instance, the Trivalent vaccine is used to protect against all three diseases - Measles, Mumps, and Rubella. Understanding these subtypes is crucial for market analysis, as they impact the overall market taxonomy and size.

In terms of Application, the market can be segmented into Pediatric Vaccination and Adult Vaccination. The Pediatric Vaccination segment dominates the market, as measles, mumps, and rubella vaccines are primarily administered to children. However, the Adult Vaccination segment is also significant, as some adults may not have received the vaccine during their childhood or may require booster shots.

Measles, Mumps and Rubella Virus Vaccine Live Segmentation Breakdown6 items

Application

Hospital

Community

Types

Child

Adult

Regional Insights

Loading chart…

The Measles, Mumps and Rubella Virus Vaccine Live market growth is expected to vary across regions, with the largest share held by North America, accounting for approximately 30% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of vaccines, government policies supporting immunization programs, and significant investments in healthcare infrastructure.

Key drivers for each region include: for North America, high ecosystem maturity, strong infrastructure, and favorable demographics; for Europe, robust policies and investments in public health, as well as a mature ecosystem; for Asia Pacific, rapid demographic changes, increasing adoption of vaccines, and significant investments in healthcare; for Latin America, government policies and investments in immunization programs, and a growing ecosystem; and for Middle East & Africa, rising adoption of vaccines, improving infrastructure, and favorable demographics.

The regional forecast indicates that the Measles, Mumps and Rubella Virus Vaccine Live market will experience significant growth in the coming years, driven by these key drivers and factors. Understanding these regional dynamics is crucial for stakeholders to navigate the market effectively and capitalize on emerging opportunities.

Competitive Landscape

The Measles, Mumps and Rubella Virus Vaccine Live market is moderately consolidated, with a mix of global players and local companies competing for market share. The Measles, Mumps and Rubella Virus Vaccine Live competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players have a strong presence, but local companies are also significant, particularly in emerging markets.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players are adapting to these challenges by focusing on specific strategic areas, as outlined below:

Merck: regional expansion

Shanghai Institute of Biological Products: vertical integration

Beijing Tiantan Biological Products: premium pricing

Merck: OEM tie-ups

Shanghai Institute of Biological Products: innovation pipeline

Beijing Tiantan Biological Products: local manufacturing

Key Measles, Mumps and Rubella Virus Vaccine Live Companies3 items

Merck

Shanghai Institute of Biological Products

Beijing Tiantan Biological Products

Market Ecosystem

The Measles, Mumps and Rubella Virus Vaccine Live ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly categorized into three stages: upstream, where raw materials and components are sourced; midstream, where vaccines are manufactured and integrated; and downstream, where vaccines are distributed and administered to end users. Value is created and captured at each stage, with technology providers and suppliers contributing to the development of vaccines, and end users ultimately benefiting from the vaccines.

Raw material suppliers — provide vaccine components

OEMs / manufacturers — produce vaccines

Distributors / channel partners — deliver vaccines to healthcare providers

Service providers / after-sales — offer vaccination services

End users / buyers — receive vaccinations

Regulators/standards bodies — oversee vaccine safety and efficacy

Data/analytics providers — track vaccination rates and outcomes

In the Measles, Mumps and Rubella Virus Vaccine Live ecosystem, control points are largely influenced by regulators and standards bodies, who enforce strict guidelines on vaccine safety and efficacy. Dependency risks arise from input constraints, such as limited supplies of raw materials, and from standards and approvals, which can vary by region. Switching costs and partnerships are also important considerations, as vaccine manufacturers and distributors often form exclusive agreements. Furthermore, the ecosystem differs by region, with varying levels of access to vaccination services and distinct regulatory frameworks. A thorough value chain analysis is necessary to understand these complex interactions and identify opportunities for improvement.

Recent Industry Insights

The Measles, Mumps and Rubella Virus Vaccine Live industry has witnessed significant developments over the last 12-18 months, shaping the Measles, Mumps and Rubella Virus Vaccine Live industry trends. Recent partnerships have focused on improving vaccine distribution and accessibility, particularly in low-income countries. Notably, mergers and acquisitions have led to the consolidation of key players, enhancing their market presence and research capabilities. Furthermore, advancements in technology have enabled the launch of new products with improved efficacy and safety profiles.

Regulatory changes have also played a crucial role in the industry, with updates to vaccination guidelines and recommendations. Additionally, there has been a shift in consumer trends, with increased awareness about the importance of vaccination, driving demand for Measles, Mumps and Rubella Virus Vaccine Live. The industry has also seen significant funding rounds and expansions, supporting research and development of new vaccine candidates and manufacturing capacities, ultimately influencing the future of the Measles, Mumps and Rubella Virus Vaccine Live industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Measles, Mumps and Rubella Virus Vaccine Live market. The market attractiveness of this sector is driven by increasing demand for vaccines, particularly in developing countries. The competitive landscape is characterized by competitive intensity, with several key players operating in the market. Looking ahead, the long-term Measles, Mumps and Rubella Virus Vaccine Live market outlook is positive, with opportunities for growth and innovation.

The innovation landscape is evolving, with ongoing research and development focused on improving vaccine efficacy and safety. However, the market is not without risks, including demand–supply balance challenges and key risk factors such as regulatory changes and supply chain disruptions. Despite these challenges, the overall outlook for the market remains strong, driven by increasing demand and ongoing innovation.

12 items

1. Executive Summary

2. Measles, Mumps and Rubella Virus Vaccine Live Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Measles, Mumps and Rubella Virus Vaccine Live Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Measles, Mumps and Rubella Virus Vaccine Live Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Measles, Mumps and Rubella Virus Vaccine Live Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Measles, Mumps and Rubella Virus Vaccine Live Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Measles, Mumps and Rubella Virus Vaccine Live Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Measles, Mumps and Rubella Virus Vaccine Live Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Measles, Mumps and Rubella Virus Vaccine Live Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Measles, Mumps and Rubella Virus Vaccine Live Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Measles, Mumps and Rubella Virus Vaccine Live Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Measles, Mumps and Rubella Virus Vaccine Live Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Measles, Mumps and Rubella Virus Vaccine Live Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Measles, Mumps and Rubella Virus Vaccine Live Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Measles, Mumps and Rubella Virus Vaccine Live Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Measles, Mumps and Rubella Virus Vaccine Live Market Competition by Key Manufacturers

9.1. Global Measles, Mumps and Rubella Virus Vaccine Live Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Measles, Mumps and Rubella Virus Vaccine Live: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Merck

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Shanghai Institute of Biological Products

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Beijing Tiantan Biological Products

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Measles, Mumps and Rubella Virus Vaccine Live Market

Figure 4: Global Measles, Mumps and Rubella Virus Vaccine Live Market: Drivers

Figure 5: Global Measles, Mumps and Rubella Virus Vaccine Live Market: Challenges

Figure 6: Global Measles, Mumps and Rubella Virus Vaccine Live Market: Trends

Figure 7: Global Measles, Mumps and Rubella Virus Vaccine Live Market: Opportunity

Figure 8: Global Measles, Mumps and Rubella Virus Vaccine Live Market: Restraint

Figure 9: Global Measles, Mumps and Rubella Virus Vaccine Live Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Measles, Mumps and Rubella Virus Vaccine Live Market Value (USD Million) By Region

Figure 19: Global Measles, Mumps and Rubella Virus Vaccine Live Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Measles, Mumps and Rubella Virus Vaccine Live Market Value (USD Million) By Region

Figure 27: Global Measles, Mumps and Rubella Virus Vaccine Live Market Share (%) By: Regions (2032)

Figure 28: Global Measles, Mumps and Rubella Virus Vaccine Live Market Volume (K) By Region

Figure 29: Global Measles, Mumps and Rubella Virus Vaccine Live Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Measles, Mumps and Rubella Virus Vaccine Live Market Value (USD Million) By Region

Figure 37: Global Measles, Mumps and Rubella Virus Vaccine Live Market Share (%) By: Regions (2032)

Figure 38: Global Measles, Mumps and Rubella Virus Vaccine Live Market Volume (K) By Region

Figure 39: Global Measles, Mumps and Rubella Virus Vaccine Live Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

101 items

Table 1: Market Segmentation Analysis

Table 2: Global Measles, Mumps and Rubella Virus Vaccine Live Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Measles, Mumps and Rubella Virus Vaccine Live Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Measles, Mumps and Rubella Virus Vaccine Live Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Measles, Mumps and Rubella Virus Vaccine Live Market Value (USD Million) By Region

Table 14: Global Measles, Mumps and Rubella Virus Vaccine Live Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Measles, Mumps and Rubella Virus Vaccine Live Market Volume (K) By Region

Table 31: Global Measles, Mumps and Rubella Virus Vaccine Live Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Measles, Mumps and Rubella Virus Vaccine Live Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Measles, Mumps and Rubella Virus Vaccine Live Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Measles, Mumps and Rubella Virus Vaccine Live Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Merck Basic Information And Sales Area

Table 52: Merck. Products Portfolio

Table 53: Shanghai Institute of Biological Products Basic Information And Sales Area

Table 54: Shanghai Institute of Biological Products. Products Portfolio

Table 55: Beijing Tiantan Biological Products Basic Information And Sales Area

Table 56: Beijing Tiantan Biological Products. Products Portfolio

Table 57: Global Market Value (USD Million) (2025-2032) By Application

Table 58: Global Market Share (%) By Application (2032)

Table 59: Global Market Value (USD Million) (2025-2032) By Types

Table 60: Global Market Share (%) By Types (2032)

Table 61: Global Market Volume (K) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Volume (K) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Measles, Mumps and Rubella Virus Vaccine Live Market Value (USD Million) By Region

Table 66: Global Measles, Mumps and Rubella Virus Vaccine Live Market Share (%) By Region (2025-2032)

Table 67: North America Market Value (USD Million) (2025-2032) By Country

Table 68: North America Market Value (USD Million) (2025-2032) By Application

Table 69: North America Market Value (USD Million) (2025-2032) By Types

Table 70: Europe Market Value (USD Million) (2025-2032) By Country

Table 71: Europe Market Value (USD Million) (2025-2032) By Application

Table 72: Europe Market Value (USD Million) (2025-2032) By Types

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 76: South America Market Value (USD Million) (2025-2032) By Country

Table 77: South America Market Value (USD Million) (2025-2032) By Application

Table 78: South America Market Value (USD Million) (2025-2032) By Types

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 82: Global Measles, Mumps and Rubella Virus Vaccine Live Market Volume (K) By Region

Table 83: Global Measles, Mumps and Rubella Virus Vaccine Live Market Share (%) By Region (2025-2032)

Table 84: North America Market Volume (K) (2025-2032) By Country

Table 85: North America Market Volume (K) (2025-2032) By Application

Table 86: North America Market Volume (K) (2025-2032) By Types

Table 87: Europe Market Volume (K) (2025-2032) By Country

Table 88: Europe Market Volume (K) (2025-2032) By Application

Table 89: Europe Market Volume (K) (2025-2032) By Types

Table 90: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 91: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 93: South America Market Volume (K) (2025-2032) By Country

Table 94: South America Market Volume (K) (2025-2032) By Application

Table 95: South America Market Volume (K) (2025-2032) By Types

Table 96: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 97: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 99: Research Programs/Design For This Report

Table 100: Key Data Information From Secondary Sources

Table 101: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Measles, Mumps and Rubella Virus Vaccine Live Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	24.05 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Shanghai Institute of Biological Products; Beijing Tiantan Biological Products
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options